Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have been assigned an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and eleven have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $31.75.

IMNM has been the topic of a number of research analyst reports. Leerink Partners set a $40.00 price objective on shares of Immunome in a research report on Monday, December 15th. Truist Financial began coverage on shares of Immunome in a research report on Monday, December 1st. They set a “buy” rating and a $36.00 price target on the stock. Wall Street Zen raised shares of Immunome from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Stephens lifted their price objective on Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a research report on Monday, November 17th. Finally, HC Wainwright began coverage on Immunome in a report on Thursday, February 12th. They set a “buy” rating and a $40.00 target price on the stock.

Insider Buying and Selling

In other Immunome news, CEO Clay B. Siegall bought 4,729 shares of the company’s stock in a transaction dated Tuesday, December 30th. The shares were purchased at an average price of $21.15 per share, for a total transaction of $100,018.35. Following the acquisition, the chief executive officer owned 665,254 shares in the company, valued at approximately $14,070,122.10. This represents a 0.72% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Philip Tsai purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was acquired at an average price of $20.49 per share, with a total value of $204,900.00. Following the completion of the purchase, the insider owned 43,300 shares in the company, valued at $887,217. This represents a 30.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 68,518 shares of company stock valued at $1,453,958 over the last ninety days. Company insiders own 7.69% of the company’s stock.

Institutional Investors Weigh In On Immunome

A number of hedge funds and other institutional investors have recently bought and sold shares of IMNM. T. Rowe Price Investment Management Inc. increased its stake in shares of Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares in the last quarter. Invesco Ltd. grew its stake in shares of Immunome by 382.1% in the 4th quarter. Invesco Ltd. now owns 270,065 shares of the company’s stock worth $5,801,000 after buying an additional 214,049 shares during the last quarter. Virtus Investment Advisers LLC increased its position in Immunome by 16.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after buying an additional 1,970 shares in the last quarter. Wellington Management Group LLP raised its stake in Immunome by 267.8% during the fourth quarter. Wellington Management Group LLP now owns 934,463 shares of the company’s stock valued at $20,072,000 after buying an additional 680,395 shares during the last quarter. Finally, SummitTX Capital L.P. bought a new stake in Immunome in the fourth quarter worth $2,741,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Stock Performance

IMNM opened at $21.80 on Tuesday. The stock has a market capitalization of $2.41 billion, a PE ratio of -7.39 and a beta of 2.32. The stock’s 50 day moving average price is $22.71 and its 200-day moving average price is $17.03. Immunome has a 52-week low of $5.15 and a 52-week high of $27.65.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.